...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Donor-specific T-cell reactivity identifies kidney transplant patients in whom immunosuppressive therapy can be safely reduced (see comments)
【24h】

Donor-specific T-cell reactivity identifies kidney transplant patients in whom immunosuppressive therapy can be safely reduced (see comments)

机译:供体特异性T细胞反应性鉴定出可以安全降低免疫抑制治疗的肾移植患者(见评论)

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: To reduce the side effects of long-term immunosuppressive therapy, stable renal transplant patients were routinely converted from cyclosporine to either azathioprine or mycophenolate mofetil. Thereafter, the azathioprine and mycophenolate mofetil dose was reduced to 75% at 4 months and to 50% at 8 months after conversion. We questioned whether the T-cell reactivity before conversion was able to predict which patients could be safely converted and tapered in their immunosuppressive load, while remaining free from acute rejection. METHODS: Before conversion, the T-cell reactivity of peripheral blood mononuclear cells against donor and third-party spleen cells were tested in mixed lymphocyte cultures. We measured the frequency of donor and third-party reactive helper T-lymphocyte (HTLpf) and cytotoxic T-lymphocyte (CTLpf) precursors and their avidity for HLA class I antigens using limiting dilution analysis. Peripheral blood mononuclear cells were also stimulated with tetanus toxoid to test the general immune response. RESULTS: The tetanus toxoid response, reactivity to donor and third-party cells as measured in mixed lymphocyte cultures and HTLpf, and the avidity of cytotoxic T-lymphocyte precursors were not predictive for the development of acute rejection. However, significant differences were found in donor-specific CTLpf before conversion, between patients with and without acute rejection after conversion in immunosuppression. The donor-specific CTLpf was significantly lower in patients without compared to those with acute rejection (P=0.01). Additionally, when no CTLpf was detectable before conversion, acute rejection did not occur after conversion. Acute rejection was only diagnosed in patients with detectable CTLpf before conversion. CONCLUSION: The number of donor-specific cytotoxic T-lymphocytes identifies patients in whom the immunosuppressive load can be safely reduced.
机译:背景:为减少长期免疫抑制治疗的副作用,稳定的肾移植患者通常从环孢素转为硫唑嘌呤或霉酚酸酯。此后,硫唑嘌呤和霉酚酸酯的剂量在转化后的4个月降低到75%,在转化后8个月降低到50%。我们质疑转化前的T细胞反应性是否能够预测哪些患者可以安全地转化并降低其免疫抑制负荷,同时保持急性排斥反应。方法:在转化之前,在混合淋巴细胞培养物中测试了外周血单核细胞对供体和第三方脾细胞的T细胞反应性。我们使用有限稀释分析法测量了供体和第三方反应性辅助T淋巴细胞(HTLpf)和细胞毒性T淋巴细胞(CTLpf)前体的频率及其对HLA I类抗原的亲和力。破伤风类毒素还刺激了外周血单核细胞,以测试一般的免疫反应。结果:破伤风类毒素反应,在混合淋巴细胞培养和HTLpf中对供体和第三方细胞的反应性以及细胞毒性T淋巴细胞前体的亲和力不能预测急性排斥反应的发展。但是,在免疫抑制转换后有或没有急性排斥反应的患者之间,转化前的供体特异性CTLpf有显着差异。没有急性排斥反应的患者与没有急性排斥反应的患者相比,供体特异性CTLpf显着降低(P = 0.01)。此外,如果在转换前未检测到CTLpf,则转换后不会发生急性排斥反应。急性排斥反应仅在转化前可检测到CTLpf的患者中诊断出来。结论:供体特异性细胞毒性T淋巴细胞的数量确定了可以安全降低免疫抑制负荷的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号